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Dr. Adam Berger Heads New 
Section of Surgical Oncology
Adam Berger, MD, FACS has been named 
Chief of the new Section of Surgical 
Oncology in the Department of Surgery. 
The section’s specialty overlaps with 
several divisions in the Department of 
Surgery and therefore includes surgeons 
specializing in many areas, including 
pancreatic cancer, breast cancer, and 
thyroid cancer. 
Dr. Berger is taking on this latest 
administrative challenge in addition to his 
ongoing clinical, research and educational 
responsibilities. His efforts have not gone 
unnoticed. As a Cancer Liaison Physician 
at Jefferson, Dr. Berger recently received 
an Outstanding Performance Award for 
going above and beyond the scope of 
the normal duties of serving as a liaison 
between the Hospital’s cancer program 
and the American College of Surgeons 
Commission on Cancer. 
As Section Chief, Dr. Berger’s first task 
will be formalizing a surgical oncology 
curriculum for medical students and 
residents. Jefferson will also be applying 
for an NIH T-32 training grant to allow 
one surgical resident to be more formally 
trained in oncologic basic science for  
two years during his or her residency.  
Dr. Berger will be a co-investigator on 
this grant. 
In addition to his clinical and educational 
responsibilities as Section Chief, Dr. 
Berger is the Principal Investigator (PI) 
for a number of national and international 
clinical studies. As a surgeon, Dr. Berger 
feels a responsibility to encourage his 
patients to enroll in clinical trials. “We are 
often the first doctor that a patient sees 
after his or her diagnosis, and we form a 
strong bond,” he says. “Part of my role is 
to advise my patients and emphasize the 
potential impact of their involvement in 
clinical trials for cancer research.” 
One such trial is a randomized 
trial of two surgical techniques for 
pancreaticojejunostomy (connecting 
the pancreas to the jejunum) in patients 
undergoing a Whipple procedure, to 
treat cancerous tumors of the pancreas. 
“There have not been a lot of randomized 
prospective trials on these techniques,” 
says Dr. Berger, “This is the largest 
study to date.” So far the technique that 
favored invagination of the pancreas 
has resulted in fewer pancreatic leaks 
and fewer adverse patient outcomes. 
Dr. Berger presented this research at the 
Annual Meeting of the Southern Surgical 
Association in 2008. 
A second trial for which Dr. Berger is a PI 
studies the use of a new drug– ZD6474–
in combination with chemotherapy and 
radiation prior to surgery for patients 
with esophageal cancer. Dr. Berger 
conceptualized and designed the study  
in consultation with AstraZeneca.  
“Most trials report a pathologically 
complete response rate of about 20 
percent,” says Dr. Berger. “So far, five 
out of eight patients (63 percent) in our 
current trial have had pathologically 
complete responses–meaning the tumor 
has been entirely eliminated–which is  
very encouraging.” 
Dr. Berger is also a surgical 
co-investigator for a multi-institutional 
trial through the Radiation Therapy 
Oncology Group, the first Phase III trial 
to compare the effects of chemotherapy 
and radiation versus chemotherapy alone 
for pancreas cancer patients following 
surgical removal of the head of the 
pancreas. “Unlike in the United States, 
European physicians tend to think the 
combined treatments are worse for the 
patient’s long-term survival and quality 
of life,” says Dr. Berger. Approximately 
900 patients will be enrolled, in Europe, 
Canada, and the United States. “This 
study has been a long time in the 
making,” says Dr. Berger, “but the results 
will be groundbreaking for how we treat 
pancreatic cancer.”
This surgical oncology expertise is now 
accessible beyond the Jefferson Center 
City campus. Dr. Berger provides surgical 
oncology services to Nazareth Hospital 
in Northeast Philadelphia as a part of the 
Jefferson Cancer Network. The Nazareth 
team also includes five Jefferson medical 
oncologists and radiation oncologists. 
Dr. Berger notes, “Our goal is to reach 
out and bring our first-rate care to 
surrounding communities.”
Joseph Cozzitorto, is a Research 
Associate at the Jefferson Center for 
Pancreatic, Biliary and Related Cancers.
How did you come to work at Jefferson?
My wife, Ellen, had been diagnosed with 
pancreatic cancer, and our physician in 
Princeton recommended that we come to 
Jefferson for her surgery. I had worked for 
25 years in the field of molecular biology, 
so during one of our visits, I inquired 
whether the department was doing any 
research. Dr. Yeo thought my experience 
was a good fit for Dr. Jonathan Brody, who 
was about to establish a new lab dedicated 
to pancreatic cancer. That was in 2006, 
and I’ve been commuting from my home in 
South Brunswick, NJ, ever since.
What did your prior experience involve?
I did Plant Molecular Biology, while 
working for EniChem America, an 
Italian startup company and American 
Cyanamid Corporation, which specializes 
in agricultural chemistry. At American 
Cyanamid I isolated genes of agronomic 
interest and generated mutations that 
would allow plants to survive in the 
presence of herbicide. I had also done 
biomedical and basic research in academia 
and for other companies in molecular 
biology. The way I look at it is that every 
other job I’ve had was a preparation for the 
work I do now.
What do you do in Dr. Brody’s lab?
I do cloning work, which involves isolating 
certain genes from cultures of mammalian 
cells or clinical samples of patient tumors 
and inserting them into plasmids so that 
they can be used in experiments. We 
also investigate drug activity in cultured 
cells that have been transfected with 
these genes. I have co-authored several 
articles on our findings. I also manage 
the lab, which includes two residents, a 
PhD investigator, a research assistant, 
and volunteers. As the lab’s Principal 
Investigator, Dr. Brody always has creative 
ideas for experiments that keep the 
projects moving forward. It’s a very team-
oriented environment.
Dr. Berger is heading the new Section of Surgical Oncology at Jefferson in Center City while 
working to expand oncology services to Northeast Philadelphia through Nazareth Hospital. 
At the same time, he is working on formalizing a curriculum and continuing his work on 
several clinical studies.
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“So far, five out of eight 
patients in our current trial 
have had pathologically 
complete responses” 
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